Abbott Labs Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Abbott Labs has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is up from 16.2% the prior year.
Abbott Labs's revenue grew a modest 4.6% year-over-year to $42.0B. This slow but positive growth earns a score of 42/100.
Abbott Labs carries a low D/E ratio of 0.26, meaning only $0.26 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Abbott Labs's current ratio of 1.67 indicates adequate short-term liquidity, earning a score of 47/100. The company can meet its near-term obligations, though with limited headroom.
Abbott Labs converts 15.1% of revenue into free cash flow ($6.4B). This strong cash generation earns a score of 76/100.
Abbott Labs earns a strong 28.1% return on equity (ROE), meaning it generates $28 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 14.8% the prior year.
Abbott Labs scores 5.23, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($195.9B) relative to total liabilities ($33.8B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Abbott Labs passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Abbott Labs generates $0.64 in operating cash flow ($8.6B OCF vs $13.4B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Abbott Labs earns $12.2 in operating income for every $1 of interest expense ($6.8B vs $559.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Abbott Labs (ABT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Abbott Labs generated $42.0B in revenue in fiscal year 2024. This represents an increase of 4.6% from the prior year.
Abbott Labs's EBITDA was $10.0B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.3% from the prior year.
Abbott Labs generated $6.4B in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 25.5% from the prior year.
Abbott Labs reported $13.4B in net income in fiscal year 2024. This represents an increase of 134.2% from the prior year.
Abbott Labs earned $7.64 per diluted share (EPS) in fiscal year 2024. This represents an increase of 134.4% from the prior year.
Abbott Labs held $7.6B in cash against $12.6B in long-term debt as of fiscal year 2024.
Abbott Labs paid $2.24 per share in dividends in fiscal year 2024. This represents an increase of 7.7% from the prior year.
Abbott Labs had 1.73B shares outstanding in fiscal year 2024. This represents a decrease of 0.0% from the prior year.
Abbott Labs's gross margin was 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.2 percentage points from the prior year.
Abbott Labs's operating margin was 16.3% in fiscal year 2024, reflecting core business profitability. This is up 0.1 percentage points from the prior year.
Abbott Labs's net profit margin was 31.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 17.7 percentage points from the prior year.
Abbott Labs's ROE was 28.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 13.3 percentage points from the prior year.
Abbott Labs invested $2.8B in research and development in fiscal year 2024. This represents an increase of 3.8% from the prior year.
Abbott Labs spent $1.3B on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 5.5% from the prior year.
Abbott Labs invested $2.2B in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 0.2% from the prior year.
ABT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4B+2.0% | $11.1B+7.6% | $10.4B-5.6% | $11.0B+5.8% | $10.4B+4.1% | $10.0B-2.7% | $10.2B+1.0% | $10.1B |
| Cost of Revenue | $5.1B+4.6% | $4.9B+8.6% | $4.5B-9.6% | $4.9B+7.4% | $4.6B+3.1% | $4.5B-2.0% | $4.6B-1.1% | $4.6B |
| Gross Profit | $6.3B+0.1% | $6.3B+6.8% | $5.9B-2.4% | $6.0B+4.5% | $5.8B+5.0% | $5.5B-3.2% | $5.7B+2.7% | $5.5B |
| R&D Expenses | $766.0M+5.7% | $725.0M+1.3% | $716.0M-4.4% | $749.0M+7.3% | $698.0M+2.0% | $684.0M-2.3% | $700.0M+4.2% | $672.0M |
| SG&A Expenses | $3.1B-1.3% | $3.1B+1.0% | $3.1B+5.3% | $2.9B-1.0% | $2.9B-0.8% | $3.0B+8.6% | $2.7B0.0% | $2.7B |
| Operating Income | $2.1B+0.2% | $2.1B+21.2% | $1.7B-11.4% | $1.9B+14.5% | $1.7B+20.4% | $1.4B-22.1% | $1.8B+8.1% | $1.6B |
| Interest Expense | $121.0M0.0% | $121.0M-7.6% | $131.0M-3.7% | $136.0M-2.9% | $140.0M-0.7% | $141.0M-11.3% | $159.0M-4.2% | $166.0M |
| Income Tax | $536.0M+44.5% | $371.0M-18.1% | $453.0M+106.3% | -$7.2B-2460.3% | $305.0M+44.5% | $211.0M+5.0% | $201.0M-14.5% | $235.0M |
| Net Income | $1.6B-7.6% | $1.8B+34.3% | $1.3B-85.6% | $9.2B+608.8% | $1.3B+6.3% | $1.2B-23.1% | $1.6B+11.0% | $1.4B |
| EPS (Diluted) | $0.94-6.9% | $1.01+32.9% | $0.76-85.6% | $5.26+610.8% | $0.74+5.7% | $0.70-23.1% | $0.91+11.0% | $0.82 |
ABT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $84.2B+0.2% | $84.0B+3.1% | $81.4B0.0% | $81.4B+11.5% | $73.0B+0.8% | $72.5B-1.0% | $73.2B+1.6% | $72.1B |
| Current Assets | $24.8B+1.5% | $24.5B+5.7% | $23.2B-2.1% | $23.7B+2.3% | $23.1B+3.3% | $22.4B-1.3% | $22.7B0.0% | $22.7B |
| Cash & Equivalents | $7.5B+8.1% | $7.0B+6.4% | $6.5B-14.2% | $7.6B+9.0% | $7.0B+11.2% | $6.3B-8.9% | $6.9B+2.8% | $6.7B |
| Inventory | $6.7B-3.5% | $7.0B+4.7% | $6.6B+7.2% | $6.2B-9.1% | $6.8B-0.2% | $6.8B+3.9% | $6.6B-1.2% | $6.7B |
| Accounts Receivable | $8.1B+2.1% | $8.0B+8.8% | $7.3B+5.8% | $6.9B+1.0% | $6.9B+3.8% | $6.6B+0.6% | $6.6B+1.0% | $6.5B |
| Goodwill | $24.0B+0.1% | $24.0B+2.5% | $23.4B+1.1% | $23.1B-0.9% | $23.3B-0.3% | $23.4B-1.3% | $23.7B+1.7% | $23.3B |
| Total Liabilities | $33.2B-0.6% | $33.4B+2.4% | $32.6B-3.3% | $33.8B+0.2% | $33.7B+0.1% | $33.7B-2.8% | $34.6B0.0% | $34.6B |
| Current Liabilities | $14.6B+8.5% | $13.4B+3.3% | $13.0B-8.1% | $14.2B+2.9% | $13.8B-1.9% | $14.0B+1.3% | $13.8B+6.1% | $13.0B |
| Long-Term Debt | $11.6B-10.3% | $12.9B+1.5% | $12.7B+0.9% | $12.6B-3.9% | $13.1B+4.5% | $12.6B-7.5% | $13.6B-6.1% | $14.5B |
| Total Equity | $51.0B+0.8% | $50.6B+3.6% | $48.8B+2.4% | $47.7B+21.2% | $39.3B+1.3% | $38.8B+0.5% | $38.6B+3.0% | $37.5B |
| Retained Earnings | $49.1B+1.3% | $48.5B+1.6% | $47.7B+1.0% | $47.3B+23.2% | $38.4B+0.9% | $38.0B+1.2% | $37.6B+1.7% | $36.9B |
ABT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.8B+36.2% | $2.0B+44.5% | $1.4B-50.6% | $2.9B+46.3% | $2.0B+91.2% | $1.0B-66.3% | $3.0B+61.9% | $1.9B |
| Capital Expenditures | $496.0M-1.2% | $502.0M+3.7% | $484.0M-32.8% | $720.0M+35.1% | $533.0M+33.9% | $398.0M-47.3% | $755.0M+34.8% | $560.0M |
| Free Cash Flow | $2.3B+48.3% | $1.5B+65.6% | $933.0M-56.6% | $2.1B+50.5% | $1.4B+127.6% | $627.0M-72.5% | $2.3B+73.3% | $1.3B |
| Investing Cash Flow | -$457.0M+21.5% | -$582.0M-23.8% | -$470.0M+45.7% | -$866.0M-91.2% | -$453.0M-6.6% | -$425.0M+48.4% | -$824.0M-30.0% | -$634.0M |
| Financing Cash Flow | -$1.8B-60.4% | -$1.1B+46.6% | -$2.1B-10.4% | -$1.9B-135.3% | -$791.0M+32.7% | -$1.2B+42.7% | -$2.1B+12.3% | -$2.3B |
| Dividends Paid | $1.0B+0.2% | $1.0B+0.3% | $1.0B+7.1% | $958.0M-0.3% | $961.0M+0.4% | $957.0M+7.8% | $888.0M0.0% | $888.0M |
| Share Buybacks | $305.0M+4983.3% | $6.0M-97.9% | $280.0M-11.1% | $315.0M+10400.0% | $3.0M-98.7% | $226.0M-12.7% | $259.0M+12850.0% | $2.0M |
ABT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.4%-1.1pp | 56.4%-0.4pp | 56.9%+1.9pp | 55.0%-0.7pp | 55.6%+0.4pp | 55.2%-0.3pp | 55.5%+0.9pp | 54.6% |
| Operating Margin | 18.1%-0.3pp | 18.4%+2.1pp | 16.3%-1.1pp | 17.4%+1.3pp | 16.1%+2.2pp | 13.9%-3.5pp | 17.4%+1.1pp | 16.2% |
| Net Margin | 14.5%-1.5pp | 16.0%+3.2pp | 12.8%-71.3pp | 84.1%+71.5pp | 12.6%+0.3pp | 12.3%-3.3pp | 15.6%+1.4pp | 14.2% |
| Return on Equity | 3.2%-0.3pp | 3.5%+0.8pp | 2.7%-16.6pp | 19.4%+16.1pp | 3.3%+0.1pp | 3.2%-1.0pp | 4.1%+0.3pp | 3.8% |
| Return on Assets | 1.9%-0.2pp | 2.1%+0.5pp | 1.6%-9.7pp | 11.3%+9.6pp | 1.8%+0.1pp | 1.7%-0.5pp | 2.2%+0.2pp | 2.0% |
| Current Ratio | 1.70-0.1 | 1.82+0.0 | 1.78+0.1 | 1.670.0 | 1.68+0.1 | 1.60-0.0 | 1.64-0.1 | 1.74 |
| Debt-to-Equity | 0.23-0.0 | 0.260.0 | 0.260.0 | 0.26-0.1 | 0.33+0.0 | 0.32-0.0 | 0.35-0.0 | 0.39 |
| FCF Margin | 20.2%+6.3pp | 13.9%+4.9pp | 9.0%-10.6pp | 19.6%+5.8pp | 13.8%+7.5pp | 6.3%-16.0pp | 22.3%+9.3pp | 13.0% |
Similar Companies
Frequently Asked Questions
What is Abbott Labs's annual revenue?
Abbott Labs (ABT) reported $42.0B in total revenue for fiscal year 2024. This represents a 4.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Abbott Labs's revenue growing?
Abbott Labs (ABT) revenue grew by 4.6% year-over-year, from $40.1B to $42.0B in fiscal year 2024.
Is Abbott Labs profitable?
Yes, Abbott Labs (ABT) reported a net income of $13.4B in fiscal year 2024, with a net profit margin of 31.9%.
What is Abbott Labs's earnings per share (EPS)?
Abbott Labs (ABT) reported diluted earnings per share of $7.64 for fiscal year 2024. This represents a 134.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Abbott Labs's EBITDA?
Abbott Labs (ABT) had EBITDA of $10.0B in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Abbott Labs have?
As of fiscal year 2024, Abbott Labs (ABT) had $7.6B in cash and equivalents against $12.6B in long-term debt.
What is Abbott Labs's gross margin?
Abbott Labs (ABT) had a gross margin of 55.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Abbott Labs's operating margin?
Abbott Labs (ABT) had an operating margin of 16.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Abbott Labs's net profit margin?
Abbott Labs (ABT) had a net profit margin of 31.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
Does Abbott Labs pay dividends?
Yes, Abbott Labs (ABT) paid $2.24 per share in dividends during fiscal year 2024.
What is Abbott Labs's return on equity (ROE)?
Abbott Labs (ABT) has a return on equity of 28.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Abbott Labs's free cash flow?
Abbott Labs (ABT) generated $6.4B in free cash flow during fiscal year 2024. This represents a 25.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Abbott Labs's operating cash flow?
Abbott Labs (ABT) generated $8.6B in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Abbott Labs's total assets?
Abbott Labs (ABT) had $81.4B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Abbott Labs's capital expenditures?
Abbott Labs (ABT) invested $2.2B in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Abbott Labs spend on research and development?
Abbott Labs (ABT) invested $2.8B in research and development during fiscal year 2024.
Does Abbott Labs buy back shares?
Yes, Abbott Labs (ABT) spent $1.3B on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Abbott Labs have outstanding?
Abbott Labs (ABT) had 1.73B shares outstanding as of fiscal year 2024.
What is Abbott Labs's current ratio?
Abbott Labs (ABT) had a current ratio of 1.67 as of fiscal year 2024, which is generally considered healthy.
What is Abbott Labs's debt-to-equity ratio?
Abbott Labs (ABT) had a debt-to-equity ratio of 0.26 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Abbott Labs's return on assets (ROA)?
Abbott Labs (ABT) had a return on assets of 16.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Abbott Labs's Altman Z-Score?
Abbott Labs (ABT) has an Altman Z-Score of 5.23, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Abbott Labs's Piotroski F-Score?
Abbott Labs (ABT) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Abbott Labs's earnings high quality?
Abbott Labs (ABT) has an earnings quality ratio of 0.64x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Abbott Labs cover its interest payments?
Abbott Labs (ABT) has an interest coverage ratio of 12.2x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Abbott Labs?
Abbott Labs (ABT) scores 74 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.